Epigenetic biomarker for preeclampsia-associated preterm birth and potential preventative medicine

Eric E Nilsson1, Paul Winchester2, Cathy Proctor2

  • 1Center for Reproductive Biology, School of Biological Sciences, Washington State University, Pullman, WA 99164-4236, United States.

Environmental Epigenetics
|November 28, 2024
PubMed

Insights

Researchers identified 389 DNA methylation differences in maternal buccal cells that may predict preeclampsia-induced preterm birth (PTB). This epigenetic biomarker shows potential for early detection and preventative strategies, achieving 78% accuracy in preliminary validation.

Area of Science:

  • Epigenetics
  • Maternal Health
  • Biomarker Discovery

Background:

  • Preterm birth (PTB) affects over 10% of births, with preeclampsia being a major subtype.
  • Current clinical methods lack reliable biomarkers to predict preeclampsia-induced PTB.
  • Epigenetic alterations, specifically DNA methylation, are explored as potential predictive markers.

Purpose of the Study:

  • To investigate DNA methylation differences in maternal buccal cells as potential biomarkers for preeclampsia-induced PTB.
  • To identify specific differential DNA methylation regions (DMRs) associated with preeclampsia.
  • To assess the preliminary accuracy of these DMRs as a predictive biomarker.

Main Methods:

  • Comparison of DNA methylation patterns in maternal buccal cells from non-preeclampsia term births versus preeclampsia PTBs.
  • Genome-wide analysis to identify differential DNA methylation regions (DMRs).
  • Cross-validation analysis for preliminary accuracy assessment.

Main Results:

  • Identified 389 genome-wide DMRs associated with preeclampsia, predominantly in low CpG density regions.
  • Found a 15% overlap with previously identified PTB buccal cell epigenetic biomarkers, highlighting unique DMRs for preeclampsia.
  • DMRs showed associations with the PI3K-Akt signaling pathway and metabolic gene families, including phospholipid signaling.
  • Preliminary validation achieved 78% accuracy for DMRs as a predictive biomarker.

Conclusions:

  • The study provides proof of concept for an epigenetic biomarker for preeclampsia-induced PTB using maternal buccal cells.
  • Identified DMRs offer potential for early detection and clinical management of preeclampsia.
  • Further clinical trials in early pregnancy are needed to validate these findings and enable preventative medicine approaches.